The overexpression of HER2 orchestrates the upregulation of LCN2 via the HER2/AKT/NF-κB signaling cascade, which is intimately associated with heightened tumorigenesis and progression in breast cancer patients (36, 37). Here, LCN2 is linked to breast carcinoma.